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Available online 3 April 2019Objective: To explore the preferences of Spanish healthcare professionals (haematologists and hospital pharma-
cists) for the treatment selection of active Chronic Lymphocytic Leukaemia (CLL) patients at first relapse,
condition that mainly afflicts older adults.
Methods: A discrete choice experiment (DCE) was conducted among haematologists and hospital pharmacists. A
literature review and a focus group informed the DCE design. CLL treatment settings were defined by seven at-
tributes: four patient/disease-related attributes (age, functional status, comorbidities, and risk of the disease)
and three treatment-related attributes (efficacy [hazard ratio of progression-free survival, HR-PFS], rate of
discontinuations due to adverse events and cost). Amixed-logit modelwas used to determine choice-based pref-
erences. Relative importance (RI) of attributes was calculated and compared between stakeholders.Willingness-
to-pay (WTP) was estimated through the DCE. Besides, nine ad-hoc questions were posed, to explore more in
depth CLL treatment decision making.
Results: A total of 130 participants (72 haematologists and 58 hospital pharmacists) answered the DCE. All attri-
butes were significant predictors of preferences (p b 0.05) in themultinomial model. Higher RI was obtained for
treatment-related attributes: the highest rated being ‘cost’ (23.8%) followed by ‘efficacy’ (20.9%). Regarding
patient-related attributes, the highest RI was obtained for ‘age’ (18.1%). No significant differences (p N 0.05) in
RI between haematologists and pharmacists were found. WTP for the treatment was higher for younger CLL
patients. Ad-hoc questions showed that patient age and functional status influence treatment decisions.
Conclusions: For healthcare professionals, ‘cost’ and ‘efficacy’ (treatment-related attributes) and age (patient-
related attribute) are the main factors that determine CLL treatment selection at first relapse. WTP decreases
as patient's age increases.











Chronic lymphocytic leukaemia (CLL) is the most common leukae-
mia in the Western world [1]. It typically afflicts older adults [2], with
a median age at diagnosis of 72 [1]. With the rapid ageing of thelymphocytic leukaemia; DCE,
rogression-free survival; NHS,
entific Tecnológic i Empresarial,
de la Plana, Castellón, Spain.
ivera).
. This is an open access article underpopulation, the incidence and prevalence of CLL among older persons
is expected to continue to increase.
Treatment of older patients remains complicated due to multiple
factors, such as the variability in fitness [3], cognition and comorbidi-
ties [2]. Particularly, treatment of relapsed CLL is highly personalized
due to the advanced age of the patient population, the risk of severe
adverse events (AEs), and the often chronic nature of this disease
[4]. Traditional intensive chemotherapy treatments for CLL can be dif-
ficult for older patients to tolerate [2,5]. More recently, novel oral
agents are proving to be both well tolerated and effective in this pop-
ulation, redefining the field of CLL therapy. Finally, new treatments
and combination therapies currently undergoing further study havethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
25C. Boqué et al. / Journal of Geriatric Oncology 11 (2020) 24–30potential utility in older patients with CLL [2], and the capacity to
modify the natural course of the disease [6].
Treatment choices for older patients must account for the interac-
tions of disease, age, and therapy, since ageing involves a progressive
decline in functional reserve and greater comorbidity; all these factors
combine to reduce life expectancy and tolerance of stress [7,8]. These
changes are universal, but occur at different rates in different individ-
uals; hence age alone is a poor prognostic factor for life expectancy
and CLL treatment tolerance [3,7]. Therefore age should not be the
sole determinant in decision-making and choice of therapy [9]. Ageism
is discriminating against individuals or groups on the basis of their
age [10] and is a topic that has been studied at length in the field of on-
cology [11], since it is an attitude frequently observed in health profes-
sionals [12]. To rely totally on chronological age in making treatment
decisions is ethically inappropriate [13,14]. Nowadays, the assessment
of physiological age, its influence on treatment tolerance, and personal-
ized treatment of CLL are emerging as key issues in the management of
CLL in older patients [7,8].
Cost considerationshave alsobeendescribed to be a factor in treating
olderCLLpatients [15]. InNationalHealthcareSystems(NHS)withpublic
funding, like the SpanishNHS, the SistemaNacional de Salud (SNS), pre-
scribingphysicians canbeconsideredasdoubleagents actingaspatients'
advocates but also as society's gatekeepers of resource use. On the one
hand, public healthcare organizationsput pressure onphysicians to con-
trol pharmaceutical spending and, on the other hand, doctors are pa-
tients' agents and as such prescribe treatments that maximize the
utility, effectiveness and quality of care in the face of economic restric-
tions [16]. In the hospital setting, the decision of incorporating drugs in
formulary is the responsibility of the Pharmacy and Therapeutics Com-
mittee [17]. In this regard, some cost awareness studies have suggested
that physicians only have an approximate knowledge of drug prices
[16] and tend to neglect price differences between products of identical
composition [18]; while other findings show that doctors feel pharma-
ceutical costs are important [16,19].
Healthcare professionals' preference over alternative treatments can
be addressed through the discrete choice experiment (DCE), a common
technique to elicit individual preferences for health care services or
technologies [20]. The DCE allows for aproximation of the decision-
making process performed by patients and professionals in real life. It
consists of presenting the participants with a free choice of two hypo-
thetical treatment options (scenarios), determined by different charac-
teristics. The answers are analyzed to estimate the relative importance
(RI) of the investigated attributes in the choice of treatments [21].
A few studies have explored patients' or professionals' preferences
for the treatment of onco-haematological malignancies, mostly related
to treatment efficacy or AEs. However, to our knowledge, neither the
importance of drug cost nor patient-or disease-related attributes have
been previously considered in preference elicitation studies in CLL,
despite they constitute key factors in treatment decision-making.
The aim of PRELIC study is to explore the preferences of Spanish
healthcare professionals (haematologists and hospital pharmacists)
for the selection of treatment for CLL patients at first relapse through a
DCE. Although health professionals are not decision makers in the
price and reimbursements processes within the SNS, we investigate
how important different attributes of the therapeutic scenario of CLL
are for them, and what factors determine their preferences, in regards
to both the patient and therapeutic characteristics. In particular, we
focus on patient's advanced age as a possible decision bias, and on the
cost of the drug.
2. Materials and Methods
2.1. Study Design and Participants
PRELIC is an observational study developed in the Spanish
healthcare setting. The participants of the study were professionalsin the field of haematology and hospital pharmacy from the SNS.
Haematologists were eligible if they had at least two years of profes-
sional experience, their professional time dedicated to clinical
assistance was over 70%, and they had expertise in CLL patients. Phar-
macists were eligible if they had at least two years of professional expe-
rience and were familiar with onco-haematological drugs.
Theminimum sample size necessary for the DCEwas established ac-
cording to the recommendation proposed by Orme [22]: n ≥ 500cta , where
n is the number of respondents, c is the maximum number of levels per
attribute, t is the number of tasks, and a is the number of alternatives
per task.
Professionalswere invited to participate through the Spanish Society
of Haematology and by a direct invitation to the pharmacy service
of hospitals and clinics. Therefore, the total number of professionals
invited was not known. They were requested via email to complete a
questionnaire (Supplementary Table S1) administered on a dedicated
study website. The study questionnaire was available from March to
May 2017.
A multidisciplinary scientific committee constituted by experts in
haematology (n = 2), hospital pharmacy (n = 2) and health economy
(n = 1), each with N15 years' professional experience, provided scien-
tific advice during the development of the study.
2.2. Discrete-Choice Experiment (DCE)
Stated-preference surveys are one of the most reliable and valid
techniques available for quantifying participants preferences. The
most commonly used stated-preference format in health care is the
DCE [23]. The DCE allows the identification and evaluation of partici-
pants' preferences for treatment and their relative importance in deci-
sion making [24]. Respondents are presented with several treatment
choice sets, each one comparing two hypothetical treatment options
(scenarios) and are asked to choose between them. Each choice set con-
sists of multiple hypothetical profiles consisting of a fixed set of criteria
(attributes), with varying values (levels) between the profiles [25]. The
DCE allows for the estimation of overall preferences for any combina-
tion of attributes and is shown to be one of the most sensitive methods
to elicit preferences, so the DCE is considered to better reflect actual de-
cision making than rating scale exercises [26]. The DCE was developed
according to good research practices recommended by International
Society for Pharmacoeconomics and Outcomes Research (ISPOR) [27].
2.2.1. Identification of Attributes and Levels
Attributes and their associated levels were initially identified from
literature review. After, a focus group with the scientific committee to
assess the relevance of the potential attributes identified in the litera-
ture, to identify attributes not retrieved in the literature and finally to
assess the comprehensibility of the attributes and levels proposed. The
result of literature review and the focus group produced seven attri-
butes with a maximum of three levels each (Table 1). Various reasons
lay behind the final selection of these attributes. The “age” attribute
was limited to elderly patients (70, 75 and85years). Two attributes (ge-
netic alterations and relapse) were redefined into one (“risk of the dis-
ease”), according to the group criteria for patients at relapse proposed in
ESMO guidelines and in the Spanish national guidelines for themanage-
ment of patients with CLL [1,28]. The range of drug costs was chosen
taking into account the annualized list prices of the main drugs used
for relapsed CLL in 2017 in Spain. Hospital medicines or hospital-
dispensed medicines are fully reimbursed in Spain; therefore, no out-
of-pocket expenses are expected from the patients.
2.2.2. Experimental Design
Experimental design techniqueswere then used to construct a series
of choice tasks from combinations of the attribute levels (called scenario
alternatives). The design was orthogonal (each pair of levels appears
Table 1
Attributes and levels included in the scenarios.
Attributes Levels








Renal failure (with or without other
comorbidities)
Other comorbidities (with functional
repercussion and normal renal function)
Risk of the
disease
Low [without 17p-deletion/p53 mutation and
late relapse (N3 years)]
High [with 17p-deletion/p53 mutation and/or
early relapse (b3 years)]
Treatment Efficacy
(HR-PFS)
HR = 0.30 (70% reduction in the risk of
progression or death)
HR = 0.45 (55% reduction in the risk of
progression or death)










ECOG: Eastern Cooperative Oncology Group; HR: Hazard Ratio; HR-PFS: Hazard Ratio of
Progression-Free Survival; AEs: Adverse Events.
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anced (each level of an attribute occurs the same number of times)
[24]. The fractional factorial analysis (main effects orthogonal matrix)
generated 36 scenarios, with a mix-and-match algorithm being used
to generate the choice sets. Dominated scenarios were identified and
minimized. To avoid participant fatigue, the 36 scenarios were distrib-
uted among three versions of questionnaires of 12 multiple-choice
sets. Each participant received a randomly assigned version of the ques-
tionnaire. Every task required to choose between two scenario alterna-
tives (Supplementary Table S2).
2.3. Ad-hoc Questions
Nine ad-hoc questions were included in the questionnaire to com-
plement the information of the DCE. The questions raised were based
on the contributions of the scientific committee about themost relevant
attributes for decision-making in CLL. This included three questions
about the importance given to age, four about functional status, and
two to estimate the willingness-to-pay (WTP) in a situation of thera-
peutic choice in CLL (Supplementary Table S1).
In question 1, professionals were asked about the “Importance of
patient's age when making decisions or recommendations about phar-
macological treatment in CLL” using a Likert scale from 1 (not impor-
tant) to 5 (very important). The range “important” was defined as the
values 4 (important) and 5 (very important) of the scale, and “not
important” as the values 1 (not important) and 2 (slightly important).
In questions 2–3, professionals assessed the “Frequency in which
patient's advanced age modifies the therapeutic regimen indicated/rec-
ommended for CLL” and the “Frequency in which patient's advanced
age impedes/hinders active treatment”, respectively, using a Likert
scale from 1 (never) to 5 (always). In question 2, the range “modifies”
was defined as the values 3 (sometimes), 4 (frequently) and 5 (always)
of the scale, and “does not modify” as the values 1 (never) and 2
(rarely). In question 3, the range “prevents/hinders” was defined as
the values 3 (sometimes), 4 (frequently) and 5 (always), and “does
not prevent/hinders” as the values 1 (never) and 2 (rarely).
In questions 4–7, participants indicated the specific value for age in
each situation. In questions 8–9, participants indicated their preferencesregarding the cost in a scale from a reference cost of €20,000 to ≥
€100,000, using intervals of €10,000.2.4. Survey Instrument
The questionnaire consisted of four parts: (i) screening questions
(selection criteria), (ii) sociodemographic data, (iii) preferences (DCE)
and (iv) ad-hoc questions. To avoid response bias due to the framing
effect of question sequence, the order of ad-hoc questions about youn-
ger and older patients were randomized in the questionnaires.2.5. Statistical Analysis
2.5.1. DCE
Based on respondents' answers to the series of choice questions, the
mixed logit model was applied to calculate the preference weights for
all attribute levels, using Stata software [29]. The model relates the
probability of choosing one treatment over another to observable differ-
ences between treatment options. The model accounts for preference
heterogeneity among respondents. It yields both a mean effect and a
standard deviation (SD) of effects across the sample [30]. The depen-
dent variable was choice, whereas independent variables were the
attribute levels.
Themixed logitmodelwasfirstly consideredwith all the variables as
categorical, except the cost, which was considered linear to estimate
WTP. In a second model, the attributes age, treatment efficacy and dis-
continuation for adverse effects were considered as linear variables.
The twomodels were compared using the Akaike Information Criterion
and the Bayesian Information Criterion [31]. In both cases, values
obtained for the linear model were lower than those obtained for the
categorical model, indicating that the linear transformations provided
a better adjustment.
The regression estimates from themixed logit model are interpreted
as the utilities associated with each respective attribute level and
referred to as part-worth utilities, which represent the relative contri-
bution of changes in treatment attributes to the choice. A higher part-
worth utility for a specific attribute level indicates a greater likelihood
that a treatment scenario including that attribute level will be chosen,
all else being equal. Part-worth utilities were subsequently used to esti-
mate RI of each studied attribute. RI was calculated as the percentage
ratio of the utility difference between the highest and lowest levels
within each attribute to the sum of differences between the highest
and lowest levels across all attributes in total. RI ranges from 0 to
100% per attribute (sum to 100% across all attributes) [32]. The inclusion
of a cost attribute in the DCE allows for a monetary estimate of utility,
theWTP [33], by applying themethodology of the marginal rate of sub-
stitution [34]. This method consists in dividing the part-worth utility of
the attribute levels (in this case, age [per year], efficacy [HR-PFS] [1%]
and % discontinuation due to AEs [1%]) by the part-worth utility of the
additional cost per month; and expressed in absolute value.2.5.2. Subgroup DCE Analysis
Professional specialty (haematology and pharmacy) and time of ex-
perience were studied as possible explanatory variables for the prefer-
ences, estimated independently for each participant. Traditional
parametric independent t-tests or the non-parametric Mann-Whitney
U test, according to data distribution, were used to assess whether RI
of attributes differed between groups. Regarding time of experience,
two subgroups were established from the cut-off point of mean years
of professional experience of the sample: professionals with lower or
higher time of experience than the mean of participants. Preferences
based on time of professional experience were then analyzed and com-




Attribute Level Coefficients SE p-value
Age (years) Per year −0.123 0.017 0.000’
70 −8.608 – –
75 −9.223 – –
85 −10.453 – –
Performance
status
Good (ECOG 0–1) 0 – –
Poor (ECOG ≥2) −1.195 0.173 0.000
Comorbidities No comorbidities 0 – –









Low 0 – –
High 0.753 0.197 0.000
Efficacy
(HR-PFS)
1% reduction in the risk of
progression/death
0.061 0.007 0.000’
HR = 0.30 (70% reduction in the
risk of progression/death)
4.263 – –
HR = 0.45 (55% reduction in the
risk of progression/death)
3.349 – –





1% −0.066 0.009 0.000’
5% −0.329 – –
15% −0.988 – –
25% −1.647 – –
Cost €1/month −0.000^ 0.000 0.000
€833.33/month (€10,000/year) 0.404 – –
€2916.67/month (€35,000/year) −1.413 – –
€5833.33/month (€70,000/year) −2.826 – –
‘Age, efficacy and discontinuation due to adverse effects were considered as linear vari-
ables, as linear transformations provided a better adjustment than the categorical
mixed-logit model. ^0.00048; AEs: % of discontinuation due to adverse events; HR-PFS:
Hazard Ratio of Progression-Free Survival; SE: Standard error.
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The importance given to age in treatment decision-making was de-
scribed by relative and absolute frequencies of the responses. The age
limit for treatment recommendation according to performance status
was estimated as mean (SD). WTP from hypothetical scenarios was de-




A total of 130 professionals from the different Spanish regions com-
pleted the electronic questionnaire and were included in the final data
analysis. Of these, 72 (55.4%) were haematologists and 58 (44.6%)
were pharmacists. Participants' characteristics are presented in
Table 2. This sample size accomplishes the minimum number of partic-
ipants according to the sample estimation, n ≥ 500c/ta, where c is the
maximum number of levels per attribute (three), t is the number of
tasks (36 tasks), and a is the number of alternatives per task (two).
3.2. Discrete Choice Experiment
3.2.1. Preferences
Table 3 and Fig. 1 present the results of the analysis of professionals'
preferences for the treatment scenario in CLL. All attributes were statis-
tically significant determinants of professionals' preferences (p b 0.05).
Among all participants, higher RI was obtained for treatment-related
attributes, thehighest ratedbeing ‘cost’ (23.8%) followedby ‘efficacy’ (haz-
ard ratio of progression-free survival, HR-PFS) (20.9%). Regarding patient-
related attributes, the highest RI was obtained for ‘age’ (18.1%) (Table 4).
3.2.2. Willingness-to-Pay
Professionals'WTP calculated from the DCE for the attributes age, ef-
ficacy (HR-PFS) and % discontinuation due to AEs is shown in Table 5.
WTP for CLL treatment increases for any of the following: lower patient
age, higher PFS or lower discontinuation rates due to AEs.
3.2.3. Factors Defining Preferences: Subgroup Analysis
In the analysis of preferences by specialty subgroup, no significant
differences in attributes RI were found between haematologists and
pharmacists (Table 4).
Two groupswere established according tomean timeof professional
experience (16.6 years): professionals with b17 years of experience
(n= 64) and professionals with ≥17 years of experience (n= 66). Sub-
group analysis ofmean attribute importance revealed that professionals
with larger experience gave stronger preference to “age” (p b 0.042)
(15.6% those with b17 years of experience, and 18.7% those with
≥17 years of experience) (Supplementary Table S3).
The analysis of preferences between haematologists with an ex-
perience b17 years (n= 33) and ≥ 17 years (n= 39) revealed signif-
icant differences, with higher RI given to “age” (p b 0.040) and lower
RI given to “% discontinuation due to AEs” by those professionalsTable 2
Participants sociodemographic characteristics.
Total (n = 13
Gender, male (%) 45.4
Age, years (mean, SD) 45.6 (8.4)
Professional experience, years (mean, SD) 16.6 (8.4)
Practice setting Public (%) 93.1
Public-private (%) 6.9
Position (%) Head of department (%) 31.5
Associate (%) 68.5
CLL patients per year (mean, SD) –
Results for the whole sample of participants are highlighted in bold.with higher time of experience (p b 0.026). The analysis of prefer-
ences in pharmacists with an experience b17 years (n = 31) and
≥17 years (n = 27) showed no significant differences (data not
shown).
3.3. Ad-hoc Questions
Questions 1–3: 90.7% of participants considered age to be important
when making decisions about CLL treatment, while only 4.6% consid-
ered that age is irrelevant for therapeutic decisions. 93% of participants
considered that age modifies the recommended therapeutic regimen
for CLL. Additionally, 77.7% of participants expressed a view that the
patient's age hinders access to active treatment.
Questions 4–7: In patients with good performance status, profes-
sionals would recommend treatment with chemo-immunotherapies
up to 80.9 (SD: 9.2) years. On the other hand, treatment with targeted
therapies would be recommended until later ages (86.5 [SD: 8.5]
years).When patient performance status is restricted, the age of recom-
mendation of active treatment for CLL decreases, recommending0) Haematologists (n = 72) Pharmacists (n = 58)
38.9 53.4
46.2 (7.5) 44.7 (9.4)






Fig. 1. Part-worth utilities within attributes. (utilities associated with each attribute level). AEs: % of discontinuation due to AEs. HR-PFS: hazard ratio of progression-free survival.
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apies up to 82.1 [SD: 9.6].
Questions 8–9: When considering a treatment offering a 1 year-
PFS gain with respect to standard treatment; professionals
expressed that the Spanish SNS should pay 12.3% less for the treat-
ment in patients aged ≥80, compared to patients aged 70 (€36,769
vs. €41,923 per year, respectively). In patients aged 70, 15.3% of pro-
fessionals considered that it would be acceptable to pay ≥€60,000 for
the treatment, whereas only 7.6% consider this range acceptable in
patients ≥80 years. Detailed results for ad-hoc questions are shown
in Supplementary Table S4.4. Discussion
CLL is a disease of old age [35], and its incidence and prevalence are
expected to increase with the ageing of the population. In this context,
there is a need to identify the factors that drive treatment decision-
making for this population group, in order to provide them with the
best treatment strategies.
In this study, a DCE was carried out to assess the importance con-
ferred by healthcare professionals (haematologists and pharmacists)
to the characteristics of the therapeutic scenario at first relapse of CLL.
A total of 130 participants (72 haematologists and 58 pharmacists) an-
swered the study questionnaire. Cost (RI: 23.8%), efficacy (RI: 20.9%)
and age (RI: 18.1%)were found to be themost important factors for pro-
fessionals when making decisions about CLL treatment. The preferredTable 4
Relative importance of attributes.
Attribute Total (n = 130) RI haematologists (n = 72)
Cost 23.8% 20.4%
Efficacy (HR-PFS) 20.9% 20.7%
Age 18.1% 16.6%
AEs 12.9% 12.9%
Performance status 11.7% 10.7%
Risk of the disease 7.4% 11.4%
Comorbidities 5.2% 7.3%
Results for the whole sample of participants are highlighted in bold.
a t-test.
b Mann-Whitney U test; AEs: % of discontinuation due to AEs; HR-PFS: Hazard Ratio of Progtreatment would be that with lower cost, higher efficacy, and for a
younger patient.
Inmany countries, pricing and public financing decisions are driven
or supported by economic evaluation studies. However, it is arguable
whether decisions should be guided by cost-related preferences in deci-
sionmakersoreven inhealthprofessionals. TheAmericanCollegeofPhy-
sicians outlined that health resource allocation decisions must focus on
medical efficacy, effectiveness, and need, with consideration of cost
based on the best available medical evidence [45]. In line with this,
cost-consciousness has been widely studied in scientific literature.
Some studies have stated that doctors have a limited or inconsistent un-
derstanding of therapeutic costs [36–38]. On the other hand, it has also
been found that doctors' stated cost-consciousness appears to be gener-
ally high, and many decisions regarding medical treatments are influ-
enced by factors other than the expected benefit to the patient,
includingconcernsaboutcostand income[39].Knowingwhat influences
physicians' attitudes towardhealth care costs is an importantmatter, be-
causemost health care expenditures are the results of doctors' decisions
[37]. This study confirms that cost is important for healthcare profes-
sionals whenmaking decisions about CLL treatment. High costs of new
CLL therapies might have influenced these preferences.
From theDCE, we also found thatWTP for the treatment depends on
patients' age, being lower for older patients. In this study we do not ex-
plore the reasons why this happens. Considering the literature, there
could be at least two explanations. First, health professionals might per-
ceive that the value of somehealth states, and consequently the value of












Age ↓1 year €253.9
Efficacy (HR-PFS) ↑1% €125.7
% discontinuation due to AEs ↓1% €136.0
AEs: % of discontinuation due to adverse events; HR-PFS: Hazard Ratio of Progression-Free
Survival.
a WTP for each attribute was estimated dividing the part-worth utility of the attribute
levels (in this case, age [per year], efficacy [HR-PFS] [1%] and % discontinuation due to AEs
[1%]) by the part-worth utility of the additional cost permonth; and expressed in absolute
value.
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considering that the value of the drug was the same regardless of age,
health professionals felt compelled by a utilitarian ethic tomaximize so-
cial benefit by allocating the most expensive resources to younger pa-
tients [42]. Of note, the greater RI assigned to chronological age than
to performance status is a fundamental issue in geriatric oncology. A pri-
mary determination when considering the appropriate therapy for an
older patient with cancer is patient's physiologic age (which assesses,
among others, comorbidity and functional status) rather than chrono-
logic age [43].
This study emphasizes the importance of taking into account
patient-centered aspects in decision-making about CLL treatment,
including both patient/disease and treatment attributes in the
therapeutic scenario of CLL. It is widely described in the literature
that the assessment of patient-related factors, such as age, comor-
bidities and functional status, is of crucial importance for an opti-
mal treatment choice in CLL [3,7,8,44]. At the same time, a few
DCE studies have analyzed the role of drug cost in determining
treatment selection preferences in oncology [45–47]. However, to
our knowledge, this is the first DCE study including both patient-
related characteristics and drug cost as attributes for CLL treatment
selection. Therefore, the importance given to the combination
of these factors in health professional preferences had not been
previously quantified.
An important limitation of a DCE study is that other attributes not
includedmay also be relevant and different levels may provide other
part-worth utilitity values and relative importance. However, we
tried to prevent this potential bias by selecting the most important
attributes from the literature, using the input of an expert panel.
Moreover, it is not known whether these unconscious preferences
translate to prescriptions [48] or into different patterns of choices
in real practice. Therefore, the study participants might make other
choices in real life. It has to be also noted that no information explor-
ing the ethical issues about balancing the dual role of participants as
patient advocates and gatekeepers of system resources was col-
lected. Sample size requirements in DCE are also a controversial
issue. No general recommendations exist, so sample sizes differ
substantially between studies and the method used is not usually re-
ported [49]. This study followed the well-established recommenda-
tions proposed by Orme [22]. According to the survey method
employed, the number of professionals invited was not known and
therefore response rate cannot be estimated. Finally, the findings of
the study significantly reflect preferences of healthcare professionals
in Spain and should be interpreted within their context. In any case,
data provide new insight into treatment decision-making in CLL.
Ad-hoc questions allowed us to explore in more detail the charac-
teristics of CLL treatment considered most relevant by experts, in-
cluding age, functional status and WTP. The vast majority of
participants (90.7%) considered that age is important when making
decisions about CLL treatment. For 93%, age modifies the recom-
mended therapeutic regimen; while 77.7% find older age impedes
access to active treatment. Functional status is a limiting factor for
accessing treatment approaches in CLL, restricting the provision ofactive treatment and determining the type of therapy. In this sense,
despite a low RI was assigned to performance status when consid-
ered jointly in the DCE, this attribute is a significant determinant of
preferences, and therefore, ad-hoc questions show that it influences
CLL decision-making. For patients with good functional status,
chemo-immunotherapy was recommended up to 80.9 (SD: 9.2)
years, while in those with limited status only up to 75.2 (SD: 10.7)
years. With regard to new targeted therapies, they were recom-
mended up to 86.5 (SD: 8.5) years for patients with good condition
and up to 82.1 (SD: 9.6) years for patients with functional limitation.
The additional questions further confirmed that patient age has
an impact on health professionals' monetary utility of CLL treatment,
in line with the results obtained from the DCE. Hence, professionals
considered that monetary utility of the treatment for the SNS in
young patients is greater than in older patients. That would suggest
health professionals might consider acceptable a higher price paid
by the SNS for younger patients than for older patients. Analysis re-
garding ad hoc questions looking at the WTP is limited by the refer-
ence cost used and the frequency of the interval of prices give to
health professionals. However, the reference cost (€20,000) was
chosen based on real annual cost of CLL treatment in Spain and the
intervals of €10,000 provide an ample range of values to health
professionals.
5. Conclusion
The study shows that for the evaluated Spanish healthcare pro-
fessionals, when making treatment decisions for CLL patients at
first relapse, treatment cost is the most important attribute,
followed by PFS and age. Age is a crucial factor, WTP for the treat-
ment being lower in older patients. It remains to be seen if these
results, and results from similar studies, will impact in future
guidelines regarding therapeutic decision-making in CLL, and
whether those guidelines will take into account physiological age
(instead of chronological age), cost/effectiveness and treatment
allocation. Extensive further research is warranted to ascertain if
the findings are confirmed in other oncological diseases of the
elderly. That would provide a wider vision on whether health pro-
fessionals' preferences point to cost before age and that affects
their decision-making process. Audits of drug utilization should
address whether older patients are being treated according to
guidelines to the same extent as younger ones. Finally, where eco-
nomic evaluation is used for pricing and financing, if studies
confirmed different values of treatment by physiological age,
more research would be needed on equity and financial aspects
of establishing differential pricing and reimbursement schemes
reflecting those differences.
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